Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Janux Therapeutics, Inc.

JANX ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$16.25

▼ -1.19%

Market Cap $993.17M · Vol 442.35K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$993.17M

Small Cap

Div Yield

N/A

EPS Growth

+4.59%

YoY

RSI (14)

32.33

Momentum

Beta

2.40

vs Market

52W High

$35.25

53.91% below

52W Low

$12.12

34.03% above

Volume

442.35K

Avg 319.48K

P/B

0.87

Price-to-book

ROE

-15.93%

Return on equity

Free Float

97.87%

Public shares

Shariah Compliance8 STANDARDS

✗ Janux Therapeutics, Inc. (JANX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does JANX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.96%

+0.78%

+18.58%

+17.04%

YTD

+17.72%

-30.61%

+64.59%

-52.71%

Financials & Valuation

TTM · Annual

Total Revenue	$10.00M
Net Income	$-113,625,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-1,576.67%
Net Profit Margin	-1,136.25%
ROE	-15.93%
ROA · ROIC	-11.02% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	85.51
P/B	0.87
P/FCF	N/A
EPS Growth	+4.59%
Outstanding Shares	61.14M

Technical Indicators

50-Day SMA	$16.91
200-Day SMA	$15.12
RSI (14)	32.33
Beta	2.40
52-Week High	$35.25
52-Week Low	$12.12

Volume Today	442.35K
Avg Daily Volume (30D)	319.48K
Relative Volume	1.38x
Volatility (10D)	57.92
Volatility (30D)	49.97
Free Float	97.87%

Analyst Consensus

BUY

Current Price $16.25

Mean Target $36.39

52W Low$12.12 52W High$35.25

Current

Target

$12.12 $35.25

Current Analyst target

+124.00% upside potential · 19 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00ZHSKH39

ISINUS47103J1051

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +0.57% ARGX.BR argenx SE -1.19% ARGX argenx SE +0.50% INSM Insmed Incorporated +2.22% 2269.HK WuXi Biologics (Cayman) Inc. +1.46%

Company Profile

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.